Scemblix (asciminib) is a new first-line option for adults with newly diagnosed Philadelphia chromosome-positive chronic myeloid leukemia in chronic phase (Ph+ CML-CP). Novartis announced yesterday ...

Scemblix, a new first-line option for adults with CML, is first to show superior efficacy and favorable safety and tolerability profile in a Phase III trial vs. all standard of care (SoC) therapies ...

Connecting decision makers to a dynamic network of information, people and ideas, Bloomberg quickly and accurately delivers business and financial information, news and insight around the world ...

The ASC4FIRST trial has shown asciminib, a novel BCR::ABL1 inhibitor, as a promising alternative to current tyrosine kinase inhibitors (TKIs) for chronic phase (CP) chronic myeloid leukaemia (CML).

Join the CML Book Club! The CTV Morning Live hosts will share a new title each month. Read along, share your thoughts, and recommend your favourite books. The CML Book Club’s first selection is ...

The author and editors take ultimate responsibility for the content. Wholesale distributors work behind the scenes, occupying a vital space in the supply chain between manufacturers and retailers.

No­var­tis’ chron­ic myeloid leukemia drug Scem­blix will now be avail­able to new­ly di­ag­nosed pa­tients, the FDA an­nounced on Tues­day.

Receive News24 Business writer-at-large Carol Paton's articles about the political economy, state-owned enterprises and energy sector.

the studio behind that country’s famous Godzilla movie monster — has unveiled a deal to acquire GKIDS, the North American indie producer and distributor. Financial terms of the agreement were ...